Smith & Nephew presents suite of new clinical evidence at World Arthroplasty Congress in Rome

Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the presentation of new clinical evidence from several key studies at the World Arthroplasty Congress (WAC) in Rome.

The suite includes key clinical studies for JOURNEY™ II BCS, which is designed to facilitate near-normal kinematics and thereby has a positive impacting on patients’ satisfaction. A multi-centre study of 20 patients¹ confirmed that the JOURNEY II BCS facilitates activity dependent knee kinematics with pronounced femoral rollback upon flexion. A second study compared 40 patients fitted with JOURNEY II BCS with 10 normal, asymptomatic knees during weight bearing motion.² Patients receiving JOURNEY II BCS implants experienced normal-like kinematic patterns during early and late flexion demonstrating adequate replication of the anterior cruciate ligament (ACL) and posterior cruciate ligament (PCL). With over 50% of patients reporting some degree of limitation to their functional activities³ after total knee arthroplasty (TKA), the design of JOURNEY II BCS aims to restore the normal, healthy knee.

Smith & Nephew will also present the first long-term results for POLARSTEM™, its cementless stem system for primary hip replacement. These confirmed that it is associated with excellent long-term component survival and functional outcomes approximately 12 years after total hip replacement (THR).⁴

“In the last year Smith & Nephew has significantly increased its investment in supporting the production of clinical evidence as we know this is vital for customers looking to assess the value of innovations in the medical devices.  We are proud to publish this suite of new clinical studies at the World Arthroplasty Congress and are on track to present more than 50 pieces of evidence in 2018. We greatly value the evidence-based conversations these allow us to have with healthcare professionals.” said Vasant Padmanabhan, President of Research & Development, Smith & Nephew.

Additional studies feature the REDAPT™ revision acetabular system fully porous cup and the NAVIO™ robotics-assisted surgical system. A full list of presentation is available by visiting Smith & Nephew’s “The Power of Patient Satisfaction” booth #23 at the World Arthroplasty Congress 19-21 March 2018. Summaries of key presentations will be provided on Smith & Nephew’s Education & Evidence website: http://www.smith-nephew.com/education in the days following this year's congress.

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew plc

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.8 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}